blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3261439

EP3261439 - METHODS AND MATERIALS FOR TREATING HUMAN IMMUNODEFICIENCY VIRUS INFECTIONS [Right-click to bookmark this link]
StatusExamination is in progress
Status updated on  15.04.2021
Database last updated on 24.08.2024
FormerRequest for examination was made
Status updated on  01.12.2017
FormerThe international publication has been made
Status updated on  25.09.2017
Most recent event   Tooltip22.06.2024New entry: Reply to examination report 
Applicant(s)For all designated states
Mayo Foundation For Medical Education And Research
Minnesota BioBusiness Center - 4th Floor
200 First Street SW
Rochester, Minnesota 55905 / US
[2018/01]
Inventor(s)01 / BADLEY, Andrew D.
706 4th Street S.W.
Rochester, Minnesota 55902 / US
 [2018/01]
Representative(s)Fish & Richardson P.C.
Highlight Business Towers
Mies-van-der-Rohe-Straße 8
80807 München / DE
[N/P]
Former [2018/01]Kunz, Herbert
Fish & Richardson P.C.
Highlight Business Towers
Mies-van-der-Rohe-Straße 8
80807 München / DE
Application number, filing date16756096.019.02.2016
[2018/01]
WO2016US18776
Priority number, dateUS201562119318P23.02.2015         Original published format: US 201562119318 P
[2018/01]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2016137844
Date:01.09.2016
Language:EN
[2016/35]
Type: A1 Application with search report 
No.:EP3261439
Date:03.01.2018
Language:EN
The application published by WIPO in one of the EPO official languages on 01.09.2016 takes the place of the publication of the European patent application.
[2018/01]
Search report(s)International search report - published on:US01.09.2016
(Supplementary) European search report - dispatched on:EP11.12.2018
ClassificationIPC:A61K31/69, A01N37/18, A61K38/55, A61P31/18, A61K38/05, A61K45/06, A61K38/20, A61K31/4402, A61K31/505, A61K31/513, A61K31/5365, A61K31/635, A61K31/675
[2023/13]
CPC:
A61K31/69 (EP,US); A61K31/4402 (EP,US); A61K31/505 (EP,US);
A61K31/513 (EP,US); A61K31/5365 (EP,US); A61K31/635 (EP,US);
A61K31/675 (EP,US); A61K38/05 (EP,US); A61K38/2013 (EP,US);
A61K38/2086 (EP,US); A61K39/21 (US); A61K45/06 (EP,US);
A61P31/18 (EP) (-)
C-Set:
A61K31/4402, A61K2300/00 (EP,US);
A61K31/505, A61K2300/00 (US,EP);
A61K31/513, A61K2300/00 (US,EP);
A61K31/635, A61K2300/00 (US,EP);
A61K31/675, A61K2300/00 (US,EP);
A61K31/69, A61K2300/00 (EP,US);
A61K38/05, A61K2300/00 (EP,US);
A61K38/2013, A61K2300/00 (EP,US);
A61K38/2086, A61K2300/00 (EP,US)
(-)
Former IPC [2019/02]A61K31/69, A01N37/18, A61K38/55, A61P31/18
Former IPC [2018/01]A01N37/18, A61K38/55, A61P31/18
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2018/01]
TitleGerman:VERFAHREN UND MATERIALIEN ZUR BEHANDLUNG MENSCHLICHER IMMUNSCHWÄCHEVIRUSINFEKTIONEN[2018/01]
English:METHODS AND MATERIALS FOR TREATING HUMAN IMMUNODEFICIENCY VIRUS INFECTIONS[2018/01]
French:MÉTHODES ET MATIÈRES POUR TRAITER DES INFECTIONS AU VIRUS DE L'IMMUNODÉFICIENCE HUMAINE[2018/01]
Entry into regional phase25.09.2017National basic fee paid 
25.09.2017Search fee paid 
25.09.2017Designation fee(s) paid 
25.09.2017Examination fee paid 
Examination procedure25.09.2017Examination requested  [2018/01]
25.09.2017Date on which the examining division has become responsible
15.07.2019Amendment by applicant (claims and/or description)
14.04.2021Despatch of a communication from the examining division (Time limit: M04)
05.08.2021Reply to a communication from the examining division
13.09.2022Despatch of a communication from the examining division (Time limit: M06)
26.01.2023Reply to a communication from the examining division
04.04.2023Despatch of a communication from the examining division (Time limit: M04)
14.08.2023Reply to a communication from the examining division
22.02.2024Despatch of a communication from the examining division (Time limit: M04)
21.06.2024Reply to a communication from the examining division
Fees paidRenewal fee
27.02.2018Renewal fee patent year 03
27.02.2019Renewal fee patent year 04
27.02.2020Renewal fee patent year 05
25.02.2021Renewal fee patent year 06
25.02.2022Renewal fee patent year 07
27.02.2023Renewal fee patent year 08
29.01.2024Renewal fee patent year 09
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:Search[X]WO2006017346  (US GOV SEC TECH TRANSFER [US], et al) [X] 1,2,5,7 * the whole document ** page 22, line 18 *;
 [X]WO2011089166  (VIROLOGIK GMBH [DE], et al) [X] 1-3,5-8,10,11,13,14 * the whole document * * page 9, lines 11-22 * * page 23, line 24 - page 24, line 28 * * page 54, line 8 - page 58, line 20 * * page 60, lines 13-26 * * page 64, lines 25-29 * * example 2 * * example 2.2.2 * * example 2.2.3 *;
 [X]  - YU L ET AL, "Proteasome inhibitors block HIV-1 replication by affecting both cellular and viral targets", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ELSEVIER, AMSTERDAM, NL, vol. 385, no. 1, doi:10.1016/J.BBRC.2009.04.156, ISSN 0006-291X, (20090717), pages 100 - 105, (20090506), XP026337672 [X] 1-3,5,11 * the whole document * * page 102, column 2, paragraph 2 - page 105, column 1, paragraph 2 *

DOI:   http://dx.doi.org/10.1016/j.bbrc.2009.04.156
International search[Y]WO0033654  (UNIV MARYLAND BIOTECH INST [US]) [Y] 11, 13 * page 5 In 11-12, page 9 In 3-6, page 71 In 20 - page 72 In 2. *;
 [Y]US2003232738  (FINKEL TERRI H [US], et al) [Y] 11, 12 * para [0010], [0022], [0079] *;
 [XY]WO2006017346  (US GOV SEC TECH TRANSFER [US], et al) [X] 1-3, 9-10 * page 8 In 15-16, In 18-20, page 9, In 4-7, page 18 In 27 - page 19 In 2, page 22 In 16-18, page 23 In 1-6, page 44 In 6-8, page 52 In 12-28 * [Y] 4-8, 11-14;
 [Y]WO2011089167  (VIROLOGIK GMBH [DE], et al) [Y] 5-8 * page 20 In 5-6, page 21 In 21-24, page35 In13-15, page 35 In 20 - page 36 In 12, page36 In 25-27, page 40 In 8-9. *;
 [Y]US2014309289  (ANDERSON JOSEPH [US], et al) [Y] 11, 14* para [0005], [0165] *;
 [Y]  - MOREAU, "Oral therapy for multiple myeloma: ixazomib arriving soon.", Blood, (20140814), vol. 124, no. 7, pages 986 - 987, XP055485036 [Y] 4 * . page 986 col 3 para 3. *
by applicantWO2006017346
 WO2011089166
    - HUTTER et al., N. Engl. J. Med., (20090000), vol. 360, pages 692 - 698
    - YU et al., Biochemical and Biophysical Research Communications, (20090717), vol. 385, no. 1, pages 100 - 105
    - BULLEN et al., Nature Medicine, (20140000), vol. 20, pages 425 - 429
    - WARRINER et al., Infect. Dis. Clin. North Am., (20140000), vol. 28, no. 3, pages 457 - 76
    - SALEH et al., Blood, (20070000), vol. 110, pages 4161 - 4164
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.